In the latest trading session, 0.42 million CorMedix Inc (NASDAQ:CRMD) shares changed hands as the company’s beta touched 1.60. With the company’s most recent per share price at $11.35 changed hands at -$0.69 or -5.73% at last look, the market valuation stands at $688.68M. CRMD’s current price is a discount, trading about -22.03% off its 52-week high of $13.85. The share price had its 52-week low at $2.57, which suggests the last value was 77.36% up since then. When we look at CorMedix Inc’s average trading volume, we note the 10-day average is 1.81 million shares, with the 3-month average coming to 1.17 million.
Analysts gave the CorMedix Inc (CRMD) stock a consensus recommendation rating of Buy, calculated at a mean rating of 1.00. If we narrow down to specifics, the data shows that 1 out of 2 analysts rate the stock as a Sell, with a further 0 assigning it an Overweight rating. Of the remaining, 0 recommended CRMD as a Hold, 1 felt it is a Buy and 0 rated the stock as Underweight. CorMedix Inc’s EPS for the current quarter is expected to be 0.05.
3 Tiny Stocks Primed to Explode
The world's greatest investor — Warren Buffett — has a simple formula for making big money in the markets. He buys up valuable assets when they are very cheap. For stock market investors that means buying up cheap small cap stocks like these with huge upside potential.
We've set up an alert service to help smart investors take full advantage of the small cap stocks primed for big returns.
Click here for full details and to join for free
Sponsored
CorMedix Inc (NASDAQ:CRMD) trade information
Instantly CRMD was in red as seen in intraday trades today. With action 11.82%, the performance over the past five days has been green. The company’s shares are showing year-to-date upside of 201.86%, with the 5-day performance at 11.82% in the green. However, in the 30-day time frame, CorMedix Inc (NASDAQ:CRMD) is 12.82% up. Looking at the short shares, we see there were 7.86 million shares sold at short interest cover period of 7.99 days.
The consensus price target for the stock as assigned by Wall Street analysts is 9, meaning bulls need a downside of -26.11% from its recent market value. According to analyst projections, CRMD’s forecast low is 9 with 9 as the target high. To hit the forecast high, the stock’s price needs a 20.7% surge from its current level, while the stock would need to tank 20.7% for it to hit the projected low.
CorMedix Inc (CRMD) estimates and forecasts
Data shows that the CorMedix Inc share is performing relatively much better than most of its peers within the same industry. As can be gleaned from the statistics, the company’s share value shot 112.95% over the past 6 months, a 49.45% in annual growth rate that is considerably higher than the industry average of 17.10%.
Consensus estimates given by 4 financial analysts project the company’s revenue in the current quarter to hit an average of 19.79M. 1 analysts are of the opinion that CorMedix Inc’s revenue for the current quarter will be 31.02M.
Looking at the company’s year-on-year earnings, data shows that the past 5-year has an earnings growth rate of 9.58%. The 2024 estimates are for CorMedix Inc earnings to increase by 45.05%.
CRMD Dividends
CorMedix Inc is expected to release its next quarterly earnings report on 2025-Mar-10.
CorMedix Inc (NASDAQ:CRMD)’s Major holders
If we look at who the major shareholders are, we find that insiders hold 0.97% of CorMedix Inc shares while 31.36% of the shares are in the hands of institutional holders. The share float percentage for the stock currently stands at 31.67%. There are 31.36% institutions holding the CorMedix Inc stock share, with BLACKROCK INC. the top institutional holder. As of 2024-06-30, the company held 6.1796% of the shares, roughly 3.55 million CRMD shares worth $15.39 million.
VANGUARD GROUP INC holds the second largest percentage of outstanding shares, with 5.0476% or 2.9 million shares worth $12.57 million as of 2024-06-30.
